IRADIMED insider Roger E. Susi files Form 4 for plan sales
Rhea-AI Filing Summary
IRADIMED (IRMD) insider activity: CEO/President/Chairman and 10% owner Roger E. Susi filed a Form 4 reporting open‑market sales on 10/27/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.
The filing shows three sales by an indirect holder: 4,242 shares at a weighted average price of $77.56, 700 shares at $78.33, and 58 shares at $79.12. Following these transactions, 2,327,500 shares were beneficially owned indirectly by the Phillip Susi 2008 Dynasty Trust. Additional indirect holdings listed include 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with a stated disclaimer of beneficial ownership except to the extent of pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Routine 10b5‑1 plan sales; neutral governance signal.
Roger E. Susi reported sales executed on 10/27/2025 under a pre‑established Rule 10b5‑1 plan. Trades were completed in multiple executions at weighted average prices of $77.56, $78.33, and $79.12, consistent with standard programmatic selling.
The filing lists post‑trade indirect holdings of 2,327,500 shares via the Phillip Susi 2008 Dynasty Trust, plus other indirect positions, alongside a disclaimer of beneficial ownership where applicable. This is informational; actual market impact depends on holder decisions and trading volumes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,242 | $77.56 | $329K |
| Sale | Common Stock | 700 | $78.33 | $55K |
| Sale | Common Stock | 58 | $79.12 | $5K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. This transaction was executed in multiple trades at prices ranging from $76.99 to $77.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $78.00 to $78.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $79.07 to $79.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
